课题基金 / 基金详情

项目摘要

项目成果

Richard Brott Halberg的其他基金

相似基金

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
DESCRIPTION (provided by applicant): Colorectal cancer is a leading cause of cancer death in the United States. Many investigators believe that a tumor is derived from a single abnormal progenitor and its descendents. The data supporting this long-held view are neither extensive nor definitive. Moreover, the experimental techniques used were heavily biased. We believe that a tumor is derived from multiple abnormal progenitors because clonal interactions among these cells provide a selective advantage during formation, growth, and progression. This hypothesis will be tested using a unique combination of newly developed mouse models, statistical analyses, and imaging techniques. We will analyze tumors from mice treated with either ethylnitrosourea (ENU) or azoxymethane (AOM), mice in which Apc is inactivated somatically by silencing, and mice in which tumorigenesis is initiated because of a mutation in the TGF2 signaling pathway (Aim 1). If polyclonality provides a selective advantage, heterotypic tumors should be common among these distinct mouse models. The tumors will be maintained in a tissue bank that will be well documented using an Access database. We will explore how heterotypic tumors emerge (Aim 2). Our initial study indicates that the most likely explanation involves clonal interactions occurring over very short distances. We will test whether polyclonality persists as tumors grow and progress from benign to malignant states (Aim 3). The results from our proposed experiments could fundamentally change the understanding of tumorigenesis in the mammalian intestine. The acceptance of this new view will undoubtedly impact the design of approaches for chemoprevention and chemotherapy. Signaling molecules mediating clonal interactions would likely be ideal targets for drug intervention. Potential mediators can be first examined utilizing our tissue bank of highly characterized tumors from a variety of mouse models. Each candidate that is still deemed interesting can then be fully tested using our experimental platform, i.e., one could determine whether elimination of the candidate through either drug intervention or genetic manipulation completely impairs the formation, growth, or progression of polyclonal tumors. PUBLIC HEALTH RELEVANCE: Initial studies from us and others indicate early adenomas are often derived from multiple progenitors, i.e., these tumors are polyclonal, not monoclonal as long believed by many investigators. Polyclonal tumors appear to emerge because of interactions occurring over very short distances. We extend our initial study by answering several fundamental questions regarding polyclonality using a unique combination of newly developed mouse models, statistical analyses, and imaging platforms. A deep understanding of this issue will likely impact the development of management strategies for intestinal cancer.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Features of the early adenoma and adjacent colon that drive progression: the role of mutation burden in normal tissue, senescent cells, and tumor clonal architecture
  • 批准号:
    10707105
  • 项目类别:
  • 资助金额:
    $31.15万
  • 财政年份:
    2022
  • 负责人:
    Richard Brott Halberg
  • 依托单位:
Features of the early adenoma and adjacent colon that drive progression: the role of mutation burden in normal tissue, senescent cells, and tumor clonal architecture
  • 批准号:
    10519075
  • 项目类别:
  • 资助金额:
    $39.03万
  • 财政年份:
    2022
  • 负责人:
    Richard Brott Halberg
  • 依托单位:
Molecular Differences Predicting Tumor Progression in Colorectal Cancer (PQ #14)
  • 批准号:
    8538333
  • 项目类别:
  • 资助金额:
    $15.38万
  • 财政年份:
    2012
  • 负责人:
    Richard Brott Halberg
  • 依托单位:
Molecular Differences Predicting Tumor Progression in Colorectal Cancer (PQ #14)
  • 批准号:
    8384609
  • 项目类别:
  • 资助金额:
    $19.64万
  • 财政年份:
    2012
  • 负责人:
    Richard Brott Halberg
  • 依托单位:
国内基金
海外基金
大肠癌发生机制的adenoma-adenocarcinoma pathway同serrated pathway的关系的研究
  • 批准号:
    30840003
  • 项目类别:
    专项基金项目
  • 资助金额:
    12.0万元
  • 批准年份:
    2008
  • 负责人:
    焦宇飞
  • 依托单位: